{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:08:14Z","timestamp":1785128894874,"version":"3.55.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00415-017-8643-4","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T02:07:23Z","timestamp":1508119643000},"page":"2409-2412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Natalizumab therapy is associated with changes in serum JC virus antibody indices over time"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-368X","authenticated-orcid":false,"given":"John","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"8643_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"issue":"2","key":"8643_CR2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A et al (2013) A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57(2):141\u2013146","journal-title":"J Clin Virol"},{"issue":"6","key":"8643_CR3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76(6):802\u2013812","journal-title":"Ann Neurol"},{"issue":"11","key":"8643_CR4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","volume":"19","author":"T Olsson","year":"2013","unstructured":"Olsson T, Achiron A, Alfredsson L et al (2013) Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 19(11):1533\u20131538","journal-title":"Mult Scler"},{"issue":"1","key":"8643_CR5","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","volume":"3","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B et al (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3(1):e195","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"14","key":"8643_CR6","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458515599681","volume":"21","author":"J Raffel","year":"2015","unstructured":"Raffel J, Gafson AR, Malik O, Nicholas R (2015) Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 21(14):1833\u20131838","journal-title":"Mult Scler"},{"issue":"Suppl 3","key":"8643_CR7","doi-asserted-by":"crossref","first-page":"iii48","DOI":"10.1136\/ard.2006.058404","volume":"65","author":"JR Berger","year":"2006","unstructured":"Berger JR (2006) Natalizumab and progressive multifocal leukoencephalopathy. Ann Rheum Dis 65(Suppl 3):iii48\u2013iii53","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8643_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","volume":"348","author":"UH Andrian von","year":"2003","unstructured":"von Andrian UH, Engelhardt B (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348(1):68\u201372","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8643-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:03:17Z","timestamp":1750946597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["8643"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8643-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}